Blue Cross Blue Shield settled a 2.67 billion antitrust lawsuit in 2020 after restricting competition for more than a decade. Payments begin in 2026. Six years later, customers get checks while insurers move on. Here is what happened and why it keeps happening.

Mount Sinai and Anthem fight over 450 million dollars while 200000 patients scramble to keep their doctors and cancer treatment. Corporate contract disputes now function as leverage tactics, turning patients into bargaining chips in rate negotiations.

The new bipartisan proposal to separate insurers, PBMs, and providers targets the financial structure behind rising costs and denials. This piece explains how ownership concentration reshaped care, why regulation failed, and what structural separation could change for patients.

We The Patients LIVE Raleigh brought patients clinicians policymakers and journalists into the same room to confront how healthcare harm actually forms. What emerged was clarity accountability and the beginning of a different kind of conversation about power trust and consequence.

Insurance companies promise reform while patients absorb delay and denial. From IVIG rejections to cancer imaging hold ups, this essay documents how prior authorization functions in real life and why patients now recognize the pattern.

Blue Cross Blue Shield of North Carolina demanded another review of an already-approved, externally-reviewed IVIG infusion—48 hours before treatment. For a patient with life-threatening hypersensitivity reactions. This is how the denial machine works, and how one patient fought back and won.